[ALA IL-8].sub.77 and [SER IL-8].sub.72 as Leukocyte adhesion inhibitors
AssigneesThe Brigham and Women's Hospital, Inc., Genentech, Inc.
InventorsMichael A. Gimbrone, Jr., Martin S. Obin, Joffre B. Baker, Caroline A. Hebert
Life of this patent
Estimating the term…
Abstract
A novel polypeptide [Ala IL-8].sub.77 is provided which is a potent modulator of neutrophil functions. The polypeptide factor and related compositions find use as anti-inflammatory agents and as therapeutics for clinical indications in which damage to vascular endothelium and other tissues occurs. The amino acid and nucleotide sequence of the factor and methods for its purification, recombinant production and pharmaceutical use are provided.
Claims3
A method of anti-inflammatory therapy comprising administering to a mammal in need of anti-inflammatory therapy a therapeutically effective amount of purified [Ala IL-8].sub.77 having leukocyte adhesion inhibition activity.
A method of treating inflammation in a mammal comprising administering a leukocyte adhesion inhibiting amount of purified [Ser IL-8].sub.72 having leukocyte adhesion inhibition activity.
Dependencies are inferred from the claim text.